Trial Profile

A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Travoprost (Primary)
Indications Ocular hypertension; Open-angle glaucoma
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Ocular Therapeutix

Most Recent Events

08 Feb 2023 Status changed from active, no longer recruiting to completed.
07 Nov 2022 According to an Ocular Therapeutix media release, topline data expected in Q4 of 2023.
11 Feb 2022 According to an Ocular Therapeutix media release, data from this trial will be presented at the Glaucoma 360 Meeting, 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com